Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

01-12-2020 | Human Immunodeficiency Virus | Case report

Repeated false reactive ADVIA centaur® and bio-rad Geenius™ HIV tests in a patient self-administering anabolic steroids

Authors: Polly Tsybina, Maurice Hennink, Tania Diener, Jessica Minion, Amanda Lang, Stephanie Lavoie, John Kim, Alexander Wong

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

An individual is considered HIV positive when a confirmatory HIV-1/HIV-2 differentiation test returns positive following an initial reactive antigen/antibody combination screen. Falsely reactive HIV screens have been reported in patients with various concomitant infectious and autoimmune conditions. Falsely positive confirmatory HIV differentiation assays are seen less frequently, but have been observed in cases of pregnancy, pulmonary embolism, and malaria.

Case presentation

A healthy 27 year-old man was referred after a reactive ADVIA Centaur® HIV Ag/Ab screen and positive Bio-Rad Geenius™ HIV 1/2 Confirmatory assay, suggesting HIV-1 infection. The patient’s HIV viral load was undetectable prior to initiation of antiretroviral therapy, and remained undetectable on subsequent testing after initiation of antiretroviral therapy. Both Centaur® and Geenius™ tests were repeated and returned reactive. As this patient was believed to be at low risk of acquiring HIV infection, samples were additionally run on Genscreen™ HIV-1 Ag assay and Fujirebio Inno-LIA™ HIV-1/2 score, with both returning non-reactive. For confirmation, the patient’s proviral HIV DNA testing was negative, confirming the initial results as being falsely positive. The patient disclosed that he had been using a variety of anabolic steroids before and during the time of HIV testing.

Discussion and conclusions

The erroneous diagnosis of HIV can result in decreased quality of life and adverse effects of antiretroviral therapy if initiated, hence the importance of interpreting the results of HIV testing in the context of an individual patient. This reports suggests a potential association between the use of anabolic steroids and falsely-reactive HIV testing.
Literature
10.
go back to reference Ly T, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods. 2007;143:86–94.CrossRef Ly T, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods. 2007;143:86–94.CrossRef
18.
go back to reference Laboratories B-R. Geenius HIV 1/2 confirmatory assay no. 883601–2013/01. Marnes-la-Coquette: Bio-Rad Laboratories; 2013. Laboratories B-R. Geenius HIV 1/2 confirmatory assay no. 883601–2013/01. Marnes-la-Coquette: Bio-Rad Laboratories; 2013.
19.
go back to reference Fujirebio Europe NV. 80540 Inno-Lia HIV I/II Score 28672 v6 2017-12-14. Gent: Fujirebio Europe N.V; 2017. Fujirebio Europe NV. 80540 Inno-Lia HIV I/II Score 28672 v6 2017-12-14. Gent: Fujirebio Europe N.V; 2017.
Metadata
Title
Repeated false reactive ADVIA centaur® and bio-rad Geenius™ HIV tests in a patient self-administering anabolic steroids
Authors
Polly Tsybina
Maurice Hennink
Tania Diener
Jessica Minion
Amanda Lang
Stephanie Lavoie
John Kim
Alexander Wong
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4722-8

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.